Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round

The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion

OneSource unveils new brand identity at CPHI Milan

Aims to achieve CDMO sales of US$ 400 million by 2028

Biocon partners with Tabuk to commercialize its Glucagon-like peptide-1 products in the Middle East

Strides secures shareholders approval for OneSource CDMO

The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE

OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

Revolutionary technology will further boost OneSource’s scientific services offerings

Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg

The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24

The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market